Dataset Information

Human CD4⁺CD25⁺CD226^- Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4⁺CD25⁺CD127^lo/- Tregs for Adoptive Cell Therapy.

ABSTRACT: Regulatory T cell (Treg) adoptive cell therapy (ACT) represents an emerging strategy for restoring immune tolerance in autoimmune diseases. Tregs are commonly purified using a CD4⁺CD25⁺CD127^lo/- gating strategy, which yields a mixed population: 1) cells expressing the transcription factors, FOXP3 and Helios, that canonically define lineage stable thymic Tregs and 2) unstable FOXP3⁺Helios^- Tregs. Our prior work identified the autoimmune disease risk-associated locus and costimulatory molecule, CD226, as being highly expressed not only on effector T cells but also, interferon-γ (IFN-γ) producing peripheral Tregs (pTreg). Thus, we sought to determine whether isolating Tregs with a CD4⁺CD25⁺CD226^- strategy

SUBMITTER: Brown ME

PROVIDER: S-EPMC9178079 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Human CD4⁺CD25⁺CD226^- Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4⁺CD25⁺CD127^lo/- Tregs for Adoptive Cell Therapy.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Human CD4+CD25+CD226- Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4+CD25+CD127lo/- Tregs for Adoptive Cell Therapy.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Human CD4⁺CD25⁺CD226^- Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4⁺CD25⁺CD127^lo/- Tregs for Adoptive Cell Therapy.